Table 1 Patient demographics and clinical characteristics

Sex

 Male

27

67.5

Age, year

61.5

12.9

Age

 < 65 years

18

45.0

 ≥ 65 years

22

55.0

Dialysis method

 Hemodialysis

15

38.5

 Hemodiafiltration

24

61.5

Dialysis history

 < 1 year

3

7.5

 ≥ 1 and < 3 years

7

17.5

 ≥ 3 years

30

75.0

Primary disease of dialysis

 Chronic glomerulonephritis^a

16

40.0

 Diabetic nephropathy

13

32.5

 Nephrosclerosis

7

17.5

 Polycystic kidney

1

2.5

 Unknown

3

7.5

Complication

 Hypertension

33

82.5

 Diabetes mellitus

16

40.0

 Dyslipidaemia

12

30.0

Prior hyperphosphatemia drug

 Calcium carbonate

10

25.0

 Calcium carbonate + lanthanum carbonate hydrate

7

17.5

 Calcium carbonate + sevelamer hydrochloride

3

7.5

 Calcium carbonate + bixalomer

3

7.5

 Calcium carbonate + iron(III) citrate hydrate

2

5.0

 Calcium carbonate + lanthanum carbonate hydrate + iron(III) citrate hydrate

1

2.5

 Lanthanum carbonate hydrate

9

22.5

 Lanthanum carbonate hydrate + iron(III) citrate hydrate

1

2.5

 Bixalomer

4

10.0

Daily dose of lanthanum carbonate hydrate, mg

1500.0

500.0

ESAs^b administration

38

95.0

Cumulative dose of ESAs, IU^c

25,315.8

18,207.7

Intravenous iron administration

5

12.5

Cumulative dose of intravenous iron, mg

160.0

0.0